Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Acupunct Meridian Stud ; 9(4): 191-9, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27555224

RESUMEN

Although acupuncture treatment is increasingly in demand among psychiatric patients, to date no studies have investigated the effectiveness of auricular acupuncture (AA) in treating anxiety disorders or major depressive disorder. Thus, this study aimed to compare the effectiveness of AA versus progressive muscle relaxation (PMR), a standardized and accepted relaxation method. We examined 162 patients with a primary diagnosis of anxiety disorder or major depressive disorder, and each patient chose between treatment with AA, executed according to the National Acupuncture Detoxification Association protocol, and treatment with PMR. Each group had treatments twice a week for 4 weeks. Before and after treatment, each participant rated four items on a visual analog scale: anxiety, tension, anger/aggression, and mood. Statistical analyses were performed with the original visual analog scale scores and the Change-Intensity Index, an appropriate indicator of the difference between two values of a variable. Our results show that treatment with AA significantly decreased tension, anxiety, and anger/aggression throughout the 4 weeks, but did not elevate mood. Between AA and PMR, no statistically significant differences were found at any time. Thus, we suggest that both AA and PMR may be useful, equally-effective additional interventions in the treatment of the above-mentioned disorders.


Asunto(s)
Acupuntura Auricular , Ansiedad/terapia , Trastorno Depresivo Mayor/terapia , Terapia por Relajación , Puntos de Acupuntura , Adulto , Ansiedad/fisiopatología , Ansiedad/psicología , Trastorno Depresivo Mayor/fisiopatología , Trastorno Depresivo Mayor/psicología , Femenino , Humanos , Masculino , Relajación Muscular , Estudios Prospectivos , Resultado del Tratamiento
2.
J Nerv Ment Dis ; 199(9): 646-52, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21878777

RESUMEN

It is still unclear whether the association between traumatic stress and physical disease is mediated by posttraumatic stress disorder (PTSD). Therefore, we examined the long-term consequences of PTSD on cardiovascular risk, stress hormones, and quality of life in a sample of former refugee children who were severely traumatized more than six decades ago. In 25 subjects with chronic PTSD and 25 trauma-controlled subjects, we measured the variables of metabolic syndrome supplemented by the ankle-brachial index and highly sensitive C-reactive protein. Quality of life was assessed using the 36-item Short-Form Health Survey. Cortisol, adrenocorticotropin-releasing hormone (ACTH), and dehydroepiandrosterone (DHEA) were measured using the low-dose-dexamethasone suppression test. In addition, salivary cortisol was assessed at 8:00 a.m., 12:00 p.m., 4:00 p.m., and 8:00 p.m. We found a significant group effect between participants with and without PTSD regarding quality of life but not in any metabolic parameter including the ankle-brachial index or cortisol, ACTH, and DHEA in plasma before and after dexamethasone or salivary cortisol. The postulated association between traumatic stress and physical illness does not appear to be mediated by PTSD in this population. Nevertheless, the search for subgroups of PTSD patients with childhood traumatization leading to different metabolic and endocrine long-term consequences in aging PTSD patients is needed.


Asunto(s)
Hidrocortisona/metabolismo , Acontecimientos que Cambian la Vida , Calidad de Vida/psicología , Refugiados/psicología , Trastornos por Estrés Postraumático/metabolismo , Hormona Adrenocorticotrópica/sangre , Anciano , Índice Tobillo Braquial , Proteína C-Reactiva/metabolismo , Deshidroepiandrosterona/sangre , Femenino , Encuestas Epidemiológicas , Humanos , Masculino , Saliva/metabolismo , Apoyo Social , Trastornos por Estrés Postraumático/psicología , Encuestas y Cuestionarios
3.
J Neurol ; 252(1): 36-41, 2005 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-15672208

RESUMEN

There is evidence from in vitro and animal experiments that oral creatine (Cr) supplementation might prevent or slow down neurodegeneration in Huntington's disease (HD). However, this neuroprotective effect could not be replicated in clinical trials, possibly owing to treatment periods being too short to impact on clinical endpoints. We used proton magnetic resonance spectroscopy ((1)H-MRS) as a surrogate marker to evaluate the effect of Cr supplementation on brain metabolite levels in HD.Twenty patients (age 46+/-7.3 years, mean duration of symptoms 4.0+/-2.1 years, number of CAG repeats 44.5+/-2.7) were included. The primary endpoint was metabolic alteration as measured by (1)H-MRS in the parieto-occipital cortex before (t1) and after 8-10 weeks (t2) of Cr administration. Secondary measures comprised the motor section of the Unified Huntington's Disease Rating Scale and the Mini Mental State Examination. (1)H-MRS showed a 15.6% decrease of unresolved glutamate (Glu)+glutamine (Gln; Glu+Gln=Glx; p<0.001) and a 7.8% decrease of Glu (p<0.027) after Cr treatment. N-acetylaspartate trended to fall (p=0.073) whereas total Cr, choline-containing compounds, glucose, and lactate remained unchanged. There was no effect on clinical rating scales. This cortical Glx and Glu decrease may be explained by Cr enhancing the energy-dependent conversion of Glu to Gln via the Glu-Gln cycle, a pathway known to be impaired in HD. Since Glu-mediated excitotoxicity is presumably pivotal in HD pathogenesis, these results indicate a therapeutic potential of Cr in HD. Thus, longterm clinical trials are warranted.


Asunto(s)
Ácido Aspártico/análogos & derivados , Encéfalo/efectos de los fármacos , Creatina/farmacología , Regulación hacia Abajo/efectos de los fármacos , Ácido Glutámico/metabolismo , Enfermedad de Huntington/tratamiento farmacológico , Fármacos Neuroprotectores/farmacología , Administración Oral , Adulto , Ácido Aspártico/metabolismo , Encéfalo/metabolismo , Encéfalo/fisiopatología , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/metabolismo , Corteza Cerebral/fisiopatología , Creatina/uso terapéutico , Regulación hacia Abajo/fisiología , Metabolismo Energético/efectos de los fármacos , Metabolismo Energético/fisiología , Femenino , Glutamina/metabolismo , Humanos , Enfermedad de Huntington/diagnóstico , Enfermedad de Huntington/metabolismo , Espectroscopía de Resonancia Magnética , Masculino , Persona de Mediana Edad , Examen Neurológico , Fármacos Neuroprotectores/uso terapéutico , Proyectos Piloto , Resultado del Tratamiento
4.
J Clin Invest ; 112(3): 423-31, 2003 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-12897210

RESUMEN

The cannabinoid receptor type 1 (CB1) and its endogenous ligands, the endocannabinoids, are involved in the regulation of food intake. Here we show that the lack of CB1 in mice with a disrupted CB1 gene causes hypophagia and leanness. As compared with WT (CB1+/+) littermates, mice lacking CB1 (CB1-/-) exhibited reduced spontaneous caloric intake and, as a consequence of reduced total fat mass, decreased body weight. In young CB1-/- mice, the lean phenotype is predominantly caused by decreased caloric intake, whereas in adult CB1-/- mice, metabolic factors appear to contribute to the lean phenotype. No significant differences between genotypes were detected regarding locomotor activity, body temperature, or energy expenditure. Hypothalamic CB1 mRNA was found to be coexpressed with neuropeptides known to modulate food intake, such as corticotropin-releasing hormone (CRH), cocaine-amphetamine-regulated transcript (CART), melanin-concentrating hormone (MCH), and preproorexin, indicating a possible role for endocannabinoid receptors within central networks governing appetite. CB1-/- mice showed significantly increased CRH mRNA levels in the paraventricular nucleus and reduced CART mRNA levels in the dorsomedial and lateral hypothalamic areas. CB1 was also detected in epidydimal mouse adipocytes, and CB1-specific activation enhanced lipogenesis in primary adipocyte cultures. Our results indicate that the cannabinoid system is an essential endogenous regulator of energy homeostasis via central orexigenic as well as peripheral lipogenic mechanisms and might therefore represent a promising target to treat diseases characterized by impaired energy balance.


Asunto(s)
Apetito/fisiología , Cannabinoides/metabolismo , Metabolismo Energético , Ácidos Grasos Insaturados/fisiología , Lípidos/biosíntesis , Receptores de Droga/fisiología , Adipocitos/metabolismo , Animales , Moduladores de Receptores de Cannabinoides , Hormona Liberadora de Corticotropina/genética , Hormona Liberadora de Corticotropina/fisiología , Ingestión de Alimentos/fisiología , Expresión Génica , Hipotálamo/fisiopatología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Neuropéptidos/genética , Neuropéptidos/fisiología , Obesidad/fisiopatología , Obesidad/terapia , Fenotipo , ARN Mensajero/genética , ARN Mensajero/metabolismo , Receptores de Cannabinoides , Receptores de Droga/deficiencia , Receptores de Droga/genética , Delgadez/fisiopatología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA